PureHoney Technologies CRO Expands Capacity with Move to New Research Facility.
Execs cite growing demand for fast analysis of functional and biochemical assays using RapidFire platform.
BILLERICA, MA, (December 12, 2016). PureHoney Technologies has moved to a larger research facility, expanding its analytical capacity using Agilent RapidFire and conventional HPLC-mass spectrometry platforms. PureHoney Technologies, a drug discovery contract research organization founded by the original developers of the RapidFire Mass Spectrometry system, uses the instrumentation to screen functional and biochemical assays with very short turnaround times. The new lab is located at 44 Manning Drive, Suite 101, Billerica, MA.
“Scientists and researchers are reaching out to us more and more to deliver fast turnaround on screening projects involving a wide range of in vitro biochemical screening assays together with cell or tissue-based functional assays,” said Can Özbal, PureHoney Technologies President and CEO, “With our larger facility and additional instrumentation we are prepared to meet the growth of applications for the ultra-fast RapidFire platform.”
Agilent Technologies and PureHoney Technologies to Develop New Applications for RapidFire/MS System
SANTA CLARA, Calif., and ACTON, Mass., Nov. 1, 2016
Agilent and PureHoney will work together to develop new applications for the Agilent RapidFire/MS System, and will independently create new workflows for pharma and biopharma research, as well as forensic toxicology and metabolomics analysis.
“Our partnership with PureHoney Technologies will enable both companies to synergistically enhance application offerings, providing scientists with a greater range of capabilities to enhance the depth and speed of pharmaceutical research,” said Monty Benefiel, Agilent vice president and general manager of the company’s Mass Spectrometry Division.
“Originally developed as a tool for label-free high-throughput screening over a decade ago, RapidFire/MS is now routinely used in applications ranging from ADME-Tox, proteomics, metabolomics, clinical research to in vivo functional assays,” said Can Özbal, PureHoney Technologies president and CEO. “We are thrilled to be partnering with Agilent to develop the next generation of applications on this versatile platform.”
The Agilent RapidFire/MS system includes drug-screening technology that provides results 10 to 100 times faster than conventional screening methods. With more than 50 peer-reviewed journal articles, RapidFire/MS is widely accepted as the benchmark platform in high-throughput mass spectrometry. This ultra-high-throughput analysis dramatically increases productivity, providing faster results.
About PureHoney Technologies
PureHoney Technologies helps pharmaceutical and biotech discovery teams accelerate drug discovery research. PureHoney offers a wide range of mass spectrometry-based analytical services specializing in functional and biochemical assays and high-throughput screening on RapidFire and conventional LC-MS platforms. Services include analytical mass spectrometry, enzymology and target characterization, custom assay development, hit identification, fragment-based screening, hit validation, structure-activity relationship screening, in vitro ADME sample screening and analytical biochemistry assays.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.